StockData

Legend Biotech vs TG Therapeutics

LEGN and TGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LEGN and TGTX compare

TG Therapeutics grew revenue faster over the last twelve months (76.1% versus 59.5% for Legend Biotech).

TG Therapeutics scores higher on the StockData Score (9 against 3 for Legend Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLEGNTGTX
Size and price
Market cap–$9.6B
Share price$16.11$62.71
Change, 1 year−46.8%102%
Change, 5 years−70.2%162%
Beta (5Y)0.800.47
Employees2,900399
StockData Score
Total score39 (better)
Valuation score01 (better)
Growth score22
Performance score04 (better)
Health score12 (better)
Dividend score00
Valuation
P/E–22.9×
P/S–12.0×
P/B–15.9×
EV/EBITDA–71.3×
P/FCF–552×
FCF yield–0.18%
Fair value–$60.66
Margin of safety–−3.4%
Growth
Revenue growth (TTM)59.5%76.1% (better)
Revenue growth, 5Y average68.8%427% (better)
Net income growth (TTM)–630%
EPS growth (TTM)–641%
Profitability
Gross margin57.2%82.4% (better)
Operating margin−4.3%17.1% (better)
Net margin–55.2%
FCF margin−9.6%2.2% (better)
Return on equity–100%
Return on invested capital–27.8%
Financial health
Debt / equity–1.23
Net debt / EBITDA–0.98
Interest coverage−2.5×3.6× (better)
Current ratio3.044.27 (better)
Altman Z-score–6.07
Piotroski F-score–4
Dividends and buybacks
Buyback yield–1.9%
Shareholder yield–1.9%
Ownership
Held by institutions28.4%72.6%
Held by insiders0.50%16.1%
Insider net buying, 12 months−$384K−$275K (better)
Superinvestors holding1–
Short interest, % of float–22.4%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.